Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Sean J. Mulvihill

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0078-8980; OpenAlex author ID A5046378649; NIH RePORTER profile ID 2294129. Sources: OpenAlex.

Their work

Papers
28 (first author 4, last author 10)
Trials
0
Grants
2
Labs led
1
Collaborators
106
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers, 1 grant · 2014: 5 papers, 1 grant · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 28

  1. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  2. Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. Last author DOI 10.1200/cci.22.00160↗
  3. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcino… Co-author DOI 10.1016/j.neo.2021.06.005↗
  4. County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma. First author DOI 10.1097/sla.0000000000003236↗
  5. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative … Co-author DOI 10.1007/s11605-018-3953-0↗
  6. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. First author DOI 10.1016/j.surg.2018.10.035↗
  7. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Co-author DOI 10.1038/s41467-018-08109-6↗
  8. Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma. First author DOI 10.1097/sla.0000000000002404↗
  9. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma. First author DOI 10.1001/jamaoncol.2018.2442↗
  10. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Co-author DOI 10.1016/j.surg.2017.10.054↗
  11. Pancreatic cancer as a sentinel for hereditary cancer predisposition. Co-author DOI 10.1186/s12885-018-4573-5↗
  12. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Last author DOI 10.1016/j.surg.2016.12.029↗
  13. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djw266↗
  14. Biomarkers in pancreatic adenocarcinoma: current perspectives. Last author DOI 10.2147/ott.s100510↗
  15. Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation. Co-author DOI 10.1007/s11605-015-2923-z↗
  16. Factors associated with improved survival after resection of pancreatic adenocarcinoma: a multivariable model. Last author DOI 10.1097/aln.0000000000000489↗
  17. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  18. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. Co-author DOI 10.1002/nbm.3198↗
  19. Screening for pancreatic cancer. Last author DOI 10.1016/j.yasu.2014.05.004↗
  20. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncb2916↗
  21. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. Last author DOI 10.1111/hpb.12199↗
  22. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  23. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Last author DOI 10.1097/mpa.0b013e31825e354d↗
  24. Screening for pancreatic cancer: why, how, and who? Last author DOI 10.1097/sla.0b013e31825ffbfb↗
  25. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Last author DOI 10.2174/1566524011313030003↗
  26. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, an… Last author DOI 10.1007/s12029-011-9251-7↗
  27. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗
  28. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Co-author DOI 10.1016/j.ccr.2011.03.002↗

Grants 2

  1. Magnetoresistive Sensor Platform for Parallel Cancer Marker Detection U01CA151650↗
  2. Advanced Development of a Multiplexed SERS-based Biomarker Detection Platform: A R33CA155586↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew A. Firpo · 21 shared papers, 2011–2023 · strength 1.54
  2. Courtney L. Scaife · 15 shared papers, 2012–2023 · strength 1.31
  3. Douglas S. Swords · 9 shared papers, 2015–2020 · strength 0.88
  4. Ignacio Garrido‐Laguna · 4 shared papers, 2019–2024 · strength 0.53
  5. Kajsa E. Affolter · 3 shared papers, 2021–2024 · strength 0.43
  6. Douglas G. Adler · 5 shared papers, 2013–2023 · strength 0.35
  7. Katherine E. Poruk · 5 shared papers, 2013–2023 · strength 0.34
  8. Marc D Porter · 2 shared grants, 2013–2014 · strength 0.33
  9. Andrew M. Lowy · 2 shared papers, 2014–2024 · strength 0.20
  10. Elena Gabriela Chiorean · 2 shared papers, 2014–2024 · strength 0.20
  11. Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.17
  12. Max Miller Wattenberg · 1 shared paper, 2024 · strength 0.17
  13. Muhammad Shaalan Beg · 1 shared paper, 2024 · strength 0.17
  14. Syed Arif Ahmad · 1 shared paper, 2024 · strength 0.17
  15. Andrea Wang‐Gillam · 1 shared paper, 2024 · strength 0.17
  16. Gregory Lawrence Beatty · 1 shared paper, 2024 · strength 0.17
  17. Philip A. Philip · 1 shared paper, 2024 · strength 0.17
  18. Anirban Maitra · 3 shared papers, 2015–2019 · strength 0.15
  19. Margaret A. Tempero · 4 shared papers, 2012–2017 · strength 0.14
  20. Josh M. Bleicher · 1 shared paper, 2023 · strength 0.14
  21. Alessandra Rosati · 1 shared paper, 2023 · strength 0.14
  22. Vincenzo De Laurenzi · 1 shared paper, 2023 · strength 0.14
  23. Maria Caterina Turco · 1 shared paper, 2023 · strength 0.14
  24. Margot De Marco · 1 shared paper, 2023 · strength 0.14
  25. Liberato Marzullo · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.